Bristol Myers Squibb Gains on Dual Phase 3 Wins and CAMZYOS Label Expansion
Bristol Myers Squibb shares gained on dual Phase 3 wins, CAMZYOS expansion and fresh analyst commentary on its IPF pipeline.
Bristol Myers Squibb Stock Jumps 6.5% on Dual Phase 3 Wins and Expanded CAMZYOS Approval
Bristol Myers Squibb shares jumped 6.5% after two positive Phase 3 updates and expanded FDA approval for CAMZYOS strengthened its clinical s…
Syndax Stock Drops 12.2% After Axatilimab Trial Miss Raises Biotech Risk Concerns
Syndax shares fell 12.2% to $14.54 in pre-open trading after its MAXPIRe Phase 2 axatilimab trial did not meet expectations.
UnitedHealth Raises 2026 Profit Outlook as Q3 Beat Overcomes Medical-Cost Pressure
UnitedHealth topped Q3 estimates and raised its 2026 profit outlook, offering a closely watched signal for managed care and healthcare spend…
STERIS to Buy Xodus Medical for $2.1 Billion in Surgical-Device Expansion
STERIS’s $2.1 billion purchase of Xodus Medical would broaden its surgical-device portfolio and underscore healthcare’s continuing consolida…
Solventum Seeks Offers for Health Information Systems Business in Potential Divestiture
Solventum is reportedly collecting offers for its Health Information Systems business, signaling a possible portfolio review without confirm…
Bristol Myers Squibb Jumps 6.5% After Twin Phase 3 Trial Wins
Bristol Myers Squibb rose 6.5% after two positive Phase 3 readouts, but mixed insider and guru positioning adds a note of caution.
Vaxcyte Stock Surges After $1.15 Billion Raise for VAX-31 Vaccine Program
Vaxcyte’s $1.15 billion public offering strengthens its balance sheet, supports VAX-31 development and reduces near-term financing risk.
STERIS’s $2.1 Billion Xodus Medical Deal Tests Healthcare M&A Appetite
STERIS’s $2.1 billion Xodus Medical agreement puts financing, dilution and medical-device M&A appetite under the microscope.
Bristol Myers Squibb Stock Jumps on Rare Double Phase 3 Success
BMY shares rose 5.7% to 6.5% after two positive Phase 3 readouts, putting pipeline value and analyst targets back in focus.
Lipocine’s TLANDO Approval Opens a New Canadian Test for $LPCN
Health Canada’s approval of TLANDO gives Lipocine a Canadian commercial pathway, with Verity Pharma targeting a launch by the end of 2026.
Merck and Moderna’s Positive Phase 3 Cancer Vaccine Data Reshape the Oncology Trade
Merck’s Keytruda gains and Moderna’s 9% stock pop highlight two distinct oncology narratives: established scale and potential mRNA growth.











